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Introduction: Despite efforts to control malaria, around 10% of the world population is at risk of 
acquiring this disease. Plasmodium falciparum accounts for the majority of severe cases and deaths. 
Malaria control programs have failed due to the therapeutic failure of first-line antimalarials and to 
parasite resistance. Thus, new and better therapeutic alternatives are required. Proteomic analysis 
allows determination of protein expression levels under drug pressure, leading to the identification of 
new therapeutic drug targets and their mechanisms of action. 
Objective: The aim of this study was to analyze qualitatively the expression of P.falciparum trophozoite 
proteins (strain ITG2), after exposure to antimalarial drugs, through a proteomic approach.
Materials and methods: In vitro cultured synchronized parasites were treated with quinine, mefloquine 
and the natural antiplasmodial diosgenone. Protein extracts were prepared and analyzed by two-
dimensional electrophoresis. The differentially expressed proteins were selected and identified by 
MALDI-TOF mass spectrometry. 
Results: The following proteins were identified among those differentially expressed in the parasite 
in the presence of the drugs tested: enolase (PF10_0155), calcium-binding protein (PF11_0098), 
chaperonin (PFL0740c), the host cell invasion protein (PF10_0268) and proteins related to redox 
processes (MAL8P1.17). These findings are consistent with results of previous studies where the 
parasite was submitted to pressure with other antimalarial drugs. 
Conclusion: The observed changes in the P. falciparum trophozoite protein profile induced by 
antimalarial drugs involved proteins mainly related to the general stress response.
Key words: Plasmodium falciparum, proteome, quinine, mefloquine. 
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Caracterización parcial del proteoma del trofozoíto de Plasmodium falciparum bajo tratamiento 
con quinina, mefloquina y el compuesto natural diosgenona 
Introducción. A pesar de los esfuerzos para controlar la malaria, esta sigue siendo un problema 
de salud pública. Plasmodium falciparum es responsable de la mayoría de los casos graves y de 
las muertes. Los programas de control de la malaria han sido cuestionados debido al fracaso del 
tratamiento y a la resistencia del parásito a los antipalúdicos de primera línea, por lo que se requieren 
nuevas y mejores alternativas. El análisis proteómico permite identificar y determinar los niveles de 
expresión de las proteínas bajo la presión de los medicamentos, lo que posibilita la identificación de 
nuevos blancos terapéuticos y mecanismos de acción.
Objetivo. Analizar cualitativamente la expresión diferencial de proteínas del citosol del trofozoíto de 
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P. falciparum bajo tratamiento con quinina, mefloquina y el compuesto natural diosgenona mediante 
una aproximación proteómica.
Materiales y métodos. Se trataron trofozoítos sincronizados y cultivados in vitro de P. falciparum 
(cepa ITG2) con quinina, mefloquina y el compuesto natural diosgenona. Los extractos proteicos 
se prepararon y analizaron por electroforesis bidimensional. Las proteínas con aparente expresión 
diferencial se seleccionaron e identificaron mediante espectrometría de masas MALDI-TOF.
Resultados. Se encontraron las siguientes proteínas diferencialmente expresadas en el trofozoíto: 
la enolasa (PF10_0155), la proteína de unión a calcio (PF11_0098), la chaperonina (PFL0740c), la 
proteína de invasión a la célula del huésped (PF10_0268) y la proteína relacionada con procesos de 
reducción y oxidación (redox) (MAL8P1.17). Estos hallazgos son congruentes con resultados previos 
de estudios en los que el parásito fue presionado con otros medicamentos antipalúdicos. 
Conclusión. Los cambios observados en el perfil de proteínas del trofozoíto de P. falciparum tratado con 
antipalúdicos involucraron preferencialmente proteínas relacionadas con la respuesta al estrés general.
Palabras clave: Plasmodium falciparum, proteoma, quinina, mefloquina.
doi: http://dx.doi.org/10.7705/biomedica.v34i2.1700
Malaria in humans is caused by five species of 
Plasmodia: Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale, Plasmodium malariae 
and Plasmodium knowlesi. The disease greatly 
compromises the health and socioeconomic 
development of communities living in tropical 
regions of the world. According to the World Health 
Organization in 2012 there were about 207 million 
cases of malaria worldwide and an estimated 
627.000 deaths with mortality rates that have 
fallen by 45% globally since 2000 (1). Malaria 
control programs in South America have failed in 
part because of parasite resistance to antimalarial 
drugs. Present strategies include the search for new 
drugs, novel therapeutic targets and combination 
therapies, but their success has been limited.
The genome sequencing of P. falciparum, 
the description of the transcriptome of the 
intraerythrocytic developmental cycle, and the 
proteome analyses have contributed to a systemic 
understanding of the disease (2,3). The quantitative 
analysis of protein levels allows studying the 
molecular profile of the parasite at different stages 
of its life cycle and under certain conditions such 
as drug pressure (3). Proteomic approaches have 
allowed the understanding of the molecular events 
occurring in the parasite in response to different 
antimalarial drugs and environments. However, 
some are based on different proteomic techniques 
with contrasting results (4-11).
The drug resistance mechanism to 4- and 8- 
aminoquinolines in P. falciparum is partially 
explained by the antimalarial drug efflux from 
the digestive vacuole and there are evidences of 
the involvement of transporters and proteases in 
the process. It is known that under pressure with 
chloroquine and other antimalarials, P. falciparum 
differentially expresses proteins related to metabolic 
processes suggesting that the therapy affects 
parasite survival and opening the possibility of 
identifying novel potential therapeutic targets (12).
The aim of this study was to characterize by two-
dimensional electrophoresis, followed by MS/MS in 
tandem, the proteome of P. falciparum trophozoites 
treated in vitro with quinine, mefloquine and the 
natural compound diosgenone (Dna). Our working 
hypothesis was that under treatment with these 
drugs, P. falciparum modifies protein expression 
and, therefore, its protein profile. To achieve the 
objective it was necessary to adapt the parasite in 
vitro culture conditions to attain high parasitemia.
Materials and methods
Parasite culture and drug treatment
The P. falciparum strain ITG2 (chloroquine 
resistant) was used in drug treatments. Parasites 
were cultured in vitro under standard conditions 
(13), synchronized as described previously (14), 
with modifications (8) to render 500 µg of protein 
per 100 ml of culture. Parasites were maintained 
in human red blood cells type A+ in RPMI 1640 
(Sigma, USA), supplemented with 10% human 
serum at 1% v/v hematocrit, in an atmosphere of 
90% N2, 5% O2 and 5% CO2, at 37°C. Gas mixture 
and medium were changed every 8 hours. The 
50% inhibitory concentrations (IC50) for quinine, 
mefloquine and the natural compound diosgenone 
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were determined as described by Smilkstein M, et 
al., (15) and calculated using the GraphPad Prism 
v5.0. For parasite drug treatments, trophozoites in 
synchronous cultures (18 hours) were treated for 
three hours with the drugs at their respective IC50. 
Before and after treatment, parasite synchrony and 
morphology were monitored by light microscopy 
of Giemsa-stained blood smears. When dead 
parasites appeared, the sample was discarded. 
Treated parasites were harvested as described 
below. All treatments were carried out in duplicate, 
in three different days, with their respective controls 
without drug.
Plasmodium falciparum protein extracts
Drug-treated and untreated parasites were collected 
by centrifugation at 600 g during 5 min at 4°C and 
the resulting pellet was further washed twice in PBS, 
pH 7.2, under the same condition. The washed 
pellet was suspended in 10mM Tris-HCl, 5% 
sorbitol, pH 7.0, supplemented with 0.15% saponin 
and protease inhibitors (Protease Inhibitor Cocktail 
Tablets, Roche), followed by incubation at 4°C for 
10 min. The suspension was centrifuged at 800 g for 
13 min at 4°C and the parasites were freeze-thawed 
15 times in liquid nitrogen and in warm water bath 
at 37°C, respectively, for 5 min each. The lysate was 
clarified by centrifugation at 800 g for 30 min at 4°C. 
Proteins in the supernatant were precipitated by 2.5 
volumes of acetone at -20°C overnight and then 
collected by centrifugation at 8,000 g for 30 minutes 
at 4°C. The supernatants were discarded whereas 
the pellet was dried at room temperature for 5 - 10 
minutes. The resulting pellet was suspended in 9M 
urea solubilizing buffer, 4% 3-[(3-cholamidopropyl) 
dimethylammonio] -1-propanesulfonate hydrate 
(CHAPS), 1% ampholytes 3-10 (Invitrogen™, 
USA), 40 mM DTT + protease inhibitors (Protease 
Inhibitor Cocktail Tablets, Roche) by vortexing. The 
protein suspension was sonicated for 10 cycles 
of 5 min at 4°C each, and clarified by centrifuging 
at 12,000 g for 30 min at 4°C. Protein content of 
extracts was quantified using the 2D Quant Kit (GE 
Healthcare). Protein integrity was checked in 12% 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide 
gel electrophoresis) (Mini-PROTEAN®, BioRad®), 
under standard conditions (running buffer Tris/
glycine/SDS pH 8.2, at 100V for 60 min).
2D-gel electrophoresis of Plasmodium 
falciparum proteins
First dimension electrophoresis was performed 
on 7 cm isoelectrofocusing (IEF) strips, pH 4-7 
(Invitrogen™, USA), actively hydrated with protein 
extracts at 50 volts for 12 hours and then focused 
to accumulate 12,000 V-h at 20°C in an IPGPhor 
III (GE Healthcare) as described (5). Proteins 
focused on strips were reduced (DTT 1X NuPAGE 
LDS buffer, Invitrogen™, USA) and alkylated (1X 
NuPAGE LDS buffer, iodoacetamide, Invitrogen™, 
USA) for 20 min each. Second dimension 
electrophoresis was run on 4-12% NuPAGE Novex 
bis-Tris (Invitrogen™, USA) and running buffer 
NuPAGE MES SDS (Invitrogen™, USA) for 135 
min at 100 V. Gels were silver stained (16).
To improve protein identification scores, gels 
were fluorescence stained using Flamingo Pink 
(BioRad®) by 2-hour incubation in 40% ethanol and 
10% acetic acid, followed by 3 hours in 1X Flamingo 
Pink stock solution. Protein spots were visualized 
under UV light in a Gel Photo documentation 
system (BioRad®) and images processed using 
the Gel-Doc EZ System (BioRad®). 
2D-gel analysis
Gels were scanned using Image Scanner III (GE 
Healthcare) and then analyzed and compared 
with the ImageMaster 2D Platinum software (GE 
Healthcare). Reference spots were selected (figure 
1) and then protein spots in the control and test 
gels were compared (Gels vs. Match). Protein 
spots with p < 0.05 were considered differentially 
expressed. Image Scanner III (GE Healthcare) was 
previously calibrated as described (10).
In-gel trypsinization of proteins and preparation 
of peptide samples for mass spectrometry (MS) 
analysis
Proteins in differential and reference spots from 
each gel were identified. Excised gel pieces of 
about 2 mm of diameter, containing spots, were 
suspended in 7% acetic acid and distained as 
described previously (16). Proteins were in-gel 
trypsinized with 10 ng/μl at 37°C overnight; the 
peptides were extracted and then suspended in 
50% (v/v) methanol and 0.1% (v/v) acetic acid. 
Peptide containing samples (0.5-0.8 μl) were 
spotted on a MALDI plate and then mixed with 
0.3–0.4 μl of saturated α-cyano-4-hydroxycinnamic 
acid (4-HCCA) in 50% ACN, and 10mM ammonium 
citrate. Plates were dried at room temperature.
Mass spectrometry
Protein samples were identified by mass spec-
trometry using an ABI 4800 MALDI TOF/TOF 
Analyzer (Applied Biosystems®, USA). MS spectra 
were executed in a Reflector Positive Ion Mode, 
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mass range 700–4,000 Da and 1,250 total shots/
spectrum. MS/MS spectra were executed in a 
Positive Ion Mode, 2 kV and 1,350 or less total 
shots/spectrum. The peptides with signal-to-noise 
ratio above 20 at the MS mode were selected 
for MS/MS run; a maximum of 45 MS/MS were 
allowed per spot. The precursor mass window was 
200 relative resolution (fwhm).
MS data analysis
All spectra were searched against Rat taxonomy, 
NCBInr database, using GPS Explorer™ Software 
Version 3.6 (ABI) and Mascot (Matrix Science) 
search engine. Variable modifications included 
oxidation (M) and acetylation (K). Mass tolerance 
was 80 ppm for precursor ions and 0.5 Da for 
fragment ions and two-missed cleavage were 
allowed. Identified peptides from P. falciparum 
proteins were confirmed in PlasmoDB (www.
plasmodb.org), Uniprot (http://www.uniprot.org) and 
their access numbers obtained. Database access 
numbers for each protein were obtained from NCBI 
(www.ncbi.nlm.nih.gov). Protein ontology was 




Table 1 summarizes the antiplasmodial half maxi-
mal inhibitory concentration IC50 (μM) for quinine, 
mefloquine and the natural compound diosgenone. 
Proteins from quinine-treated parasites
The two-dimensional protein profile of trophozoites 
(18 hours post culture) treated at a 201 nM final 
concentration of quinine for 3 hours is shown in 
figure 1B. Proteins stained with Flamingo™ Pink 
were marked as follows: Differentially expressed 
(squares), landmarks (triangles) and randomly 
identified proteins (circles). The identified proteins 
are organized in table 2, and their corresponding 
peptide sequences are in table 3. Seven out of 15 
proteins were identified as belonging to human red 
blood cells (Homo sapiens), as observed in other 
P. falciparum proteome analyses (7).
Proteins from mefloquine-treated parasites
The two-dimensional protein profile of trophozoites 
(18 hours post culture) treated with 35.4 nM 
mefloquine for 3 hours is shown in figure 1D. 
Proteins were stained with Flamingo Pink 
(BioRad®) and the spots in the gel were marked 
as follows: Differentially expressed (squares), 
landmarks (triangles) and others (arrows). The 
identified proteins are listed in table 4 and their 
corresponding peptide sequences in table 5. Eight 
out of 31 proteins were identified as belonging to 
the human red blood cells (H. sapiens) and 23 are 
parasite proteins (figure 1D, table 4).
Proteins from diosgenone-treated parasites
The two-dimensional protein profile of trophozoites 
(18 hours post culture) treated with 53.2 nM 
diosgenone for 3 hours is shown in figure 1F. 
Proteins in the gel were stained with Flamingo 
Pink (BioRad®).The identified proteins are listed in 
table 6 and the corresponding peptide sequences 
of those differentially expressed are shown in table 
7. Three out of 12 were identified as belonging to 
human red blood cells (H. sapiens) and 9 were 
parasite proteins (figure 1F, table 6).
Discussion
We found very few proteins differentially expressed 
by the parasite under quinine, mefloquine and 
diosgenone treatments relative to the control at 
the resolution of the 2D-gel electrophoresis. In 
contrast to previous reports, we did not observe 
alterations in the levels of human proteins in the 
parasite extracts upon drug treatment (6,7,17). 
All three drugs affected the expression of 
parasite proteins involved in the stress response 
relative to the control. Quinine and diosgenone 
induced differential expression of the merozoite 
surface protein 7 precursor (PF13_0197) and the 
endoplasmic reticulum-resident calcium binding 
protein (PF11_0098) (tables 3 and 7). It is well 
known that aryl amino alcohols, such as quinine 
and mefloquine, interact with hemozoin and inhibit 
its crystallization in vitro (18). Interestingly, in the 
present work we showed that these drugs appar-
ently affect expression of parasite proteins that 
are not biochemically related to that process. 
Such was the case of the enolase (PF10_0155) 
(spot 6, figure 1B and spot 20, figure 1D), a highly 
active metalloenzyme during the intraerythrocytic 
stage (19) that mediates the conversion of 
2-phosphoglycericacid into phosphoenolpyruvate 
in glycolysis, the main ener-getic process of the 
Table 1. Antiplasmodial half maximal inhibitory concentration 
(LC50) for quinine, mefloquine and the natural compound 
diosgenone on Plasmodium falciparum strain ITG2
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Figure 1. 2D protein patterns of Plasmodium falciparum trophozoites treated with quinine (B), mefloquine (D) and diosgenone (F). 
A, C and E are control gels. 
Triangles: Landmarks. Squares: Differentially expressed proteins. Circles: Random identified proteins 
intraerythrocytic form of the parasite (20). Enolase 
has been identified as an abundant protein in two-
dimensional gels (6). The differential expression of 
enolase has been reported in the parasite under 
pressure with artemether-lumefatrine (6) and 
doxycycline (10). However, this was not observed 
when the parasite was treated with pyrimethamine 
(7). The diverse localization of P. falciparum enolase 
suggests that, apart from its catalytic activity, it 
might play other biological roles. For instance, 
enolase localized on the merozoite surface may be 
involved in red blood cell invasion, vacuolar enolase 
243














































































































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10 23 14 15 20 22 24 27




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Biomédica 2014;34:237-49Segura C, Cuesta-Astroz Y, Nunes-Batista C, et al.
may be involved in food vacuole formation and/or 
development, while nuclear enolase may play a 
role in transcription (21). Therefore, it seems that 
many drugs can induce over-expression of enolase 
in the parasite.
Effect of quinine on Plasmodium falciparum 
protein profile
Quinine treated parasites produced a reduced 
amount of heat shock protein 70 (HSP-70) 
(Pf10875w) (spot 7, figure 1, A and B) relative to 
the untreated cells. This protein is localized in the 
endoplasmic reticulum (ER) at high levels in the 
exoerythrocytic stages and trophozoites, and it has 
also been shown that it is involved in the develop-
ment and pathogenesis of malaria (22). In vitro 
P. falciparum produces 87% of its total protein 
as new proteins in 48 hours (12). Thus, Hsp70 
might assist protein folding through the parasite 
life cycle. On the other hand, fevers caused by the 
parasite add a further stress to its protein-folding 
machinery (22). 
Differential expression of heat shock proteins is a 
typical stress-response of the parasites to the toxic 
effects of drugs (i.e., quinine). However, variations 
in the expression level of heat shock proteins are 
needed to allow the parasite to adapt to environ-
mental changes and for its maturation in the host. 
HSP-70 has been found upregulated in the parasite 
under treatment with artemether-lumefantrine (6) 
and an oxidized form of Hsp70 has also been 
found upon CQ treatment (8). Our observations, 
and those from other studies, clearly suggest that 
drugs induce differential expression of this particular 
HSP-70 in P. falciparum (Pf10875w).
It has been observed that antimalarials have 
contrasting effects on the expression of enolase 
(4,6,7). Glycolytic enzymes seem to have reduced 
expression in a chloroquine resistant strain 
of parasites treated with artemisinin, but over-
expression when treated with lumefantrine (3 fold) 
(6). The apparent change in expression of enolase, 
also a glycolytic enzyme, induced by quinine here 
reported, is consistent with these previous findings 
(6). Quinine and lumefantrine belong to the same 
amino-alcohol group, whereas artemisinin is a 
sesquiterpenlactone. Thus, specific effects of drugs 
on the expression of aldolase seem to be apparent. 
The parasite endoplasmic reticulum-resident 
calcium binding protein (PF11_0098) has been 
proposed to play a role in protein trafficking in 
the malaria parasite (23). Here we showed that 
quinine and diosgenone increased the level of this 
protein (spot 9, figure 1B, and spot 3, figure 1F). 
Calcium storage is critical for parasite cell mobility 
and invasion (24).Therefore, overexpression of 
the calcium binding protein (PF11_0098) might 
be an important strategy for the maintenance of 
calcium homeostasis in the parasite cells. Similar 
increase in the calcium binding protein level 
has also been observed in P. falciparum under 
the artemether/lumefantrine combination (6) and 
other experimental antiplasmodials (4). Thus, the 
increased expression of this protein in quinine 
and diosgenone treated cells suggests that they 
interfere with P. falciparum calcium homeostasis.
Interestingly, quinine downregulated and diosgenone 
upregulated the merozoite surface protein 7 (MSP7) 
(PF13_0197) (spot 5, figure 1, A and F), which is 
localized in the cytoplasm of trophozoites. MSP7, 
a peripheral membrane protein, is the precursor of 
the 22 kDa protein (MSP722) and of the 19 kDa 
protein (MSP719) found on the merozoite surface 
and non-covalently associated to the merozoite 
surface protein 1 (MSP1) complex that is shed upon 
erythrocyte invasion (25). MSP7 and its orthologous 
probably have a specific function either in the 
development of the merozoite or in parasite release 
from the erythrocyte, most likely via interaction 
with MSP1. MSP7 is translocated to the merozoite 
surface via interaction with MSP1, suggesting 
a possible role in invasion (25). This particular 
observation deserves further investigation. In the 
case of quinine, a recognized antimalarial drug, 
the downregulation of MSP7 might have effects on 
the parasite maturation and red blood cell release, 
on merozoite binding, as well as in invasion. In the 
case of diosgenone, the over-expression of MSP7 
is difficult to frame in the light of its apoptotic activity 
in the parasite, but it might occur as part of the 
apoptotic effects induced by the drug (26). MSP-7 
has been reported as differentially expressed in the 
trophozoite stage under different treatments (4,6).
Effect of mefloquine on Plasmodium falciparum 
protein profile
Mefloquine downregulated the expression of the 
eukaryotic translation initiation factor 5a, putative 
EIF-5A (PFL0210c) (spot 10, figure 1C and D) 
localized in the cytoplasm. Factor EIF-5A in 
P. falciparum is a highly conserved essential 
protein, which contains the unique amino acid 
hypusine (27). The aminoacid hypusine and its 
deoxyhypusine hydroxylase have been proposed 
as putative, novel antimalarial-drug targets (28). 
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Factor EIF-5A has been identified in P. falciparum 
trophozoites (6), but it has not been previously 
reported as differentially expressed under pressure 
with antimalarials. Thus, it is of special interest 
to further study the effect of mefloquine on the 
parasite and its hypothetical target.
Circumsporozoite related antigen EXP-1 (PF11_ 
0224) (spot 23 fig 1D) was upregulated by 
mefloquine. EXP-1 is a negatively charged integral 
protein located at the endoplasmic reticulum (ER) 
in the intraerythrocytic stages (29,30). EXP-1 has 
been identified by mass spectrometry (31) and 
found differentially expressed in chloroquine 
resistant/sensitive strains relative to the wild-
type strain (17). It has been demonstrated that 
chloroquine significantly induces the expression 
of EXP-1 in resistant P. falciparum strains (K1 – 
Dd2), but downregulates it in sensitive ones (3D7 
– HB3) (17). Findings here reported agree with 
the above observations. In our hands, mefloquine 
upregulated EXP-1 expression in the chloroquine 
resistant P. falciparum ITG2. EXP-1 has, in 
fact, been considered a chloroquine resistance 
marker (17) and we propose that it could also 
be used as a marker of mefloquine resistance. 
Further investigation is needed to establish the 
role of EXP-1 in the parasite and its relation 
with the chloroquine resistance phenotype and 
mefloquine treatment.
The merozoite capping protein 1 (MCP-1)
(PF10_0268) (spot 14, figure 1D), a protein related 
to the entry into the host cell, was upregulated by 
mefloquine. MCP-1 is a highly conserved protein 
that is one of the components of the invasion 
machinery of the parasite. Plasmepsin III, a histo-
aspartic protease (PF14_0078) (spot 15, figure 1D) 
also was upregulated by mefloquine in the parasite. 
Hemoglobin degradation is a metabolic process 
central to the growth and maturation of the malaria 
parasite P. falciparum. Plasmepsins (PMs) initiate 
hemoglobin degradation and have been identified 
and extensively characterized (26). Plasmepsin 
III is one of the 10 plasmepsins coded in the P. 
falciparum genome and the protein is located in 
the food vacuole. Thus, it has been proposed as 
a potential anti-malarial therapeutic target (32). 
Upregulation of this protein by mefloquine suggests 
increased hemoglobin degradation, which agrees 
with the known mode of action of the drug. This 
protein has also been found differentially expressed 
in the parasite treated with doxycycline, relative to 
the control (10). 
The 10 kDa chaperonin (PFL0740c) (spot 22, 
figure 1D) was upregulated by mefloquine. This 
co-chaperonin localizes in the mitochondria of 
P. falciparum and, with chaperonin 60 (cpn60 
or GroEL), an ATPase, assists the folding and 
assembly of proteins in the mitochondrial matrix 
(33). The apparent differential expression of 10 
kDa chaperonin in response to mefloquine and 
its localization deserve further investigation. The 
differential expression of the chaperonin proteins 
under different drug treatments in P. falciparum has 
been reported previously (4,10).
The conserved Plasmodium protein of unknown 
function (PF14_0046) (spot 24, figure 1D) was 
upregulated by mefloquine. This protein is localized 
in the endoplasmic reticulum (ER) and shares highly 
amino-acidic identity with a protein of unknown 
function from P. vivax (PVX_086190) (65%) and 
another from P. knowlesi (PKH_134200) (63%). 
This protein does not align with proteins from other 
parasites suggesting that it is unique to the genus 
Plasmodium. Our results suggest a possible role for 
PF14_0046 in the parasite response to mefloquine.
The disulfide isomerase (MAL8P1.17) (spot 
27, figure 1D) is an enzyme of the endoplasmic 
reticulum and displays typical biochemical functions 
of disulphide isomerase, namely oxidase/isomerase, 
reductase and a chaperone-like activity. Pf52 con-
tains domains of thiol: disulfide oxidoreductases, 
and it has been proposed as a potential parasite 
therapeutic target (33,34).
Effect of diosgenone on Plasmodium falciparum 
protein profile
Diosgenone, a triterpene of 30 carbons, induces 
parasites death in the intraerythrocytic stages 
(35). Treatment of P. falciparum trophozoites with 
diosgenone caused overexpression of the following 
proteins: The merozoite capping protein 1 (MCP-1) 
(PF10_0268) localized in the nucleus and related 
to the entry into the host cell; the endoplasmic 
reticulum-resident calcium binding protein (PF11_ 
0098), and the merozoite surface protein 7 (MSP7) 
(PF13_0197). Interestingly, expression of the latter 
two proteins appears to be controlled also by quinine, 
which caused upregulation of the endoplasmic 
reticulum-resident calcium binding protein and 
downregulation of the merozoite surface protein 
7. This observation suggests that diosgenone, 
quinine and mefloquine regulate the expression of 
similar proteins in P. falciparum trophozoites. More 
sensitive techniques will be required to confirm this 
interesting observation.
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Four out of five proteins upregulated by the drugs 
under study are localized in the endoplasmic 
reticulum suggesting increased protein packing 
and trafficking due to the synthesis of proteins for 
detoxification and oxidative stress. The upregulation 
of disulfide isomerase was evidenced by mefloquine 
treatment. It is expected that minor parasite 
proteins, differentially expressed in the presence 
of the antimalarial drugs, could also be identified if 
high-sensitivity techniques were used. In general, 
our results have shown that in the presence of the 
antimalarials quinine, mefloquine and the natural 
compound diosgenone, parasite proteins related 
to redox and energy metabolism, synthesis and 
transport had their expression levels altered.
Two-dimensional gel electrophoresis-based prote-
ome of humans and rodents in different experimental 
settings revealed similar protein expression patterns 
(36). It has been reported that the glycolytic enzyme 
enolase is the most frequently identified among 
proteins expressed differentially in nearly every 
third experiment. Similarly, the heat-shock proteins 
27 (HSP27) and 60 (HSP60) are also induced under 
many conditions and have been found expressed 
in about 30 percent of human and rodent samples 
(36). These findings suggest that they are typical 
cellular stress response proteins (33).
By using a proteomics approach, we detected 
changes in the P. falciparum protein expression 
profile, following treatment with quinine, mefloquine 
and diosgenone, relative to the control. A similar 
protein pattern emerged: Enolase, chaperonins, 
disulphide isomerases and the endoplasmic 
reticulum-resident calcium binding protein were 
the major differentially expressed proteins in P. 
falciparum treated cells under the experimental 
conditions used in this work. However, highly 
sensitive techniques such as SILAC (stable isotope 
labeling) and MudPIT (Multi-Dimensional Protein 
Identification) have made it possible to identify 
over 1,000 proteins in drug treated parasites in 
one experiment, from which approximately 50 were 
regulated relative to the control (9). About 40% 
of the identified and regulated proteins were of 
unknown functions (9), showing that a high number 
of P. falciparum proteins remain to be characterized 
for a better understanding of the mechanisms by 
which drugs affect the parasite physiology.
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